OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer

OncoSec Medical Incorporated ONCS announced early clinical data from an investigator-sponsored trial of TAVO in combination with Bristol-Myers Squibb Co's BMY intravenous Opdivo (nivolumab).
TAVO is OncoSec's proprietary interleukin 12 (IL-12) encoding plasmid delivered by intratumoral electroporation (TAVO-EP).
The trial enrolled patients with high-risk operable locoregional advanced stage IIIB-D or stage IVA melanoma.
Related: OncoSec Cuts Workforce, Prioritizes Pipeline.
A preoperative overall response rate was observed in 7 of 10 patients (70%) consisting of 4 patients with complete response (CR) and three patients with partial response (PR).
Two patients had stable disease, and one showed progressive disease.
One patient with a PR declined surgery due to a significant response after neoadjuvant treatment.
At the time of surgery, 8 of 9 (88.9%) evaluated patients had a major pathologic response, and 6 of 9 patients (66.7%) had a pathological CR. No disease recurrence has been observed at a median follow-up of 7 months from the surgery date.
Overall, the combination treatment was well tolerated, and no patient discontinued neoadjuvant treatment due to toxicity. Patients continue to enroll.
Price Action: ONCS shares are up 1.99% at $4.10 during after-hours trading on Tuesday.